NCT04957485 Phase 2 Active not recruiting
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS Study sponsor: SIGA Technologies
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-01-01 Estimated
Enrollment · participants 100 Actual
Source updated 2026-09-14 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology